research Upadacitinib: A New Weapon for the Treatment of Twenty-Nail Dystrophy
Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
Search
for
Sort by
Research
120-150 / 863 results 
research Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
New medications could improve treatment for severe alopecia areata in Australia.
research Successful treatment of severe diffuse alopecia areata with abrocitinib
Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
research Dual Relief: How Atopic Dermatitis Treatments Affect Alopecia Areata—A Small Retrospective Cohort Study
Most patients improved in both atopic dermatitis and alopecia areata with certain treatments, but some had worsened symptoms, suggesting personalized care is needed.
research Unexpected Extensive Hair Whitening Following Baricitinib Treatment for Alopecia Universalis: A Case Report and Mechanistic Insights
Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.
research Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
research Upadacitinib for the treatment of alopecia areata – A case report
Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 is generally safe for treating alopecia areata.
research Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about?
People with alopecia areata may have a higher risk of blood clots.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Citrullination at the Inflammatory Skin Barrier
A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.
research Overview of alopecia areata for managed care and payer stakeholders in the United States
Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
research Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
research Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
research Drug Armamentarium for alopecia areata
No cure exists for alopecia areata, and treatments are personalized.
research Tratamiento de la alopecia areata, un recorrido desde las opciones terapéuticas clásicas hasta los nuevos fármacos aparecidos en los últimos años
Alopecia areata is hard to treat, but new targeted therapies show promise.
research Alopecia Areata
Alopecia Areata is an unpredictable autoimmune hair loss condition with limited and variable treatment effectiveness.
research Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
Ruxolitinib effectively and safely regrows hair in alopecia patients.
research Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report
Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
research 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
research 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
Baricitinib significantly improves hair regrowth in severe alopecia areata.
research Ivarmacitinib stimulates hair regrowth in severe alopecia areata
Ivarmacitinib effectively regrows hair in severe alopecia areata.
research Spotlight in Plastic Surgery: October 2022
Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
research Possible Involvement of Skin‐Resident Memory T Cells in Refractory Chronic Alopecia Areata
Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
research Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
research Lack of efficacy of apremilast in 9 patients with severe alopecia areata
Apremilast did not work for treating severe alopecia areata.
research Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
Low-dose tofacitinib is effective and cheaper for severe alopecia areata.